Vertex Pharmaceuticals (VRTX US)
VRTX US$529.69
20 minute delayed
14 days free access
Join Market Matters and get full access to all our Opinion + Action
Performance
Advanced charting functionality with the ability to amend timeframes, chart type & indicator selection, powered by TradingView.
Share price activity
Displays share price activity. Volume = number of shares traded, Turnover = value of shares traded, VWAP = volume-weighted average price for the day, sourced from Morningstar.
- Last (Price)
- 529.69
- Change
- ▲ 8.66 (1.66)
- Bid / Ask
- 532.38 - 545.00
- Volume
- 446,074
- Turnover
- 186,154,018
- Open
- 514.45
- Day Range
- 514.45 - 534.83
- VWAP
- 528.90
- Prev Close
- 521.03
- Last Trade
- 28/10 4:00pm
Key information
Displays key information on the security, sourced from Morningstar.
- Sector
- Healthcare
- Shares Issued
- 253,805,417
- NTA/Share
- 67.54
- Last Dividend
- —
- Dividend Ex Date
- —
- Dividend Pay Date
- —
Current (USD) · FY2025
Displays key financial data for the most recent fiscal year, in millions. Note - Per share data is in local currency terms irrespective of reporting currency, and may be different to the stated currency, sourced from Morningstar.
- Revenue
- 12,001.30
- EBITDA
- 4,375.40
- Profit
- 3,953.20
- Earnings Per Share (EPS)
- 15.32
- Dividend Per Share (DPS)
- —
- Yield %
- 0.00
- Market Cap
- 134,255.72
- Price to Earnings Ratio (P/E)
- 30.85
Estimates (USD) · FY2027
Displays consensus analyst’s estimates for key measures for the next fiscal year, sourced from Morningstar.
- Revenue
- 14,635.50
- EBITDA
- 6,272.43
- Profit
- 5,445.27
- Earnings Per Share (EPS)
- 21.49
- Dividend Per Share (DPS)
- 0.00
Quantitative rating
Displays Morningstar’s Quantitative Equity Research Rating for the security: a star rating from 1 (overvalued) to 5 (undervalued) from the share price against a fair value estimated by a statistical model of Morningstar’s analyst ratings, with the model’s economic moat, financial health and fair value uncertainty, sourced from Morningstar.
Overvalued
- Economic Moat
- Narrow
- Financial Health
- Strong
- Uncertainty
- Medium
Morningstar Quantitative Rating as of 28 OCT 2026.
Quantitative Equity Rating Methodology – view here
Fair value estimate
Displays Morningstar’s quantitative fair value estimate for the security against the current share price, with the band around it: the five-star price below which the model would rate the stock five stars and the one-star price above which it would rate it one star, sourced from Morningstar.
Five-star price 401.68 Fair value 463.11 One-star price 533.94
Morningstar Quantitative Rating as of 28 OCT 2026.
Quantitative valuation
Displays where the share price sits in Morningstar’s quantitative fair value band, from the five-star price (undervalued) to the one-star price (overvalued), with the fair value estimate, the price to fair value ratio, the model’s valuation label and its uncertainty rating, sourced from Morningstar.
Buy
Sell
- Fair Value
- 463.11
- Price / Fair Value
- 1.14
- Valuation
- Overvalued
- Uncertainty
- Medium
Morningstar Quantitative Rating as of 28 OCT 2026. The slider runs from the five-star price (401.68) to the one-star price (533.94).
Displays useful ratios for the security, NB the pricing date used, sourced from Morningstar.
| Ratios |
|---|
| Currency (Price/reporting): USD/USD |
| Exchange Rate: 1.0000 |
Price, volume and trading statistics for the security, sourced from Morningstar.
| Price - closing or last bid | 529.69 |
| Price - 12 month high | 560.25 |
| Price - 12 month low | 403.57 |
| Pricing date | 27 OCT 2026 |
| Volume - avg. trading volume for the last ten days | 1.42 |
| Market capitalization | 134,255.72 |
| 12 Month High price date | 3 SEP 2026 |
| 12 Month Low price date | 4 NOV 2025 |
| Volume - avg. trading volume for the last 3 months | 1.18 |
| Price - 1 Day % Change | 1.66% |
| Price - 13 week price percent change | 8.01% |
| Price - 26 week price percent change | 23.14% |
| Price - 5 Day % Change | 0.99% |
| Price - 52 week price percent change | 25.40% |
| Price - YTD price percent change | 16.74% |
| Price % Change Month To Date | 0.38% |
Earnings, dividends, cash flow and book value per share, sourced from Morningstar.
| EPS excluding extraordinary items - most recent fiscal year | 15.320 |
| EPS excluding extraordinary items - trailing 12 month | 17.170 |
| EPS Normalized - most recent fiscal year | 18.400 |
| Revenue/share - most recent fiscal year | 46.517 |
| Revenue/share - trailing 12 month | 49.121 |
| Book value per share - most recent fiscal year | 73.490 |
| Book value per share - most recent quarter | 79.921 |
| Book value (tangible) per share - most recent fiscal year | 67.536 |
| Book value (tangible) per share - most recent quarter | 73.998 |
| Cash per share - most recent fiscal year | 20.020 |
| Cash per share - most recent quarter | 24.249 |
| Cash Flow per share - most recent fiscal year | 18.723 |
| Cash Flow per share - trailing 12 month | 19.362 |
| Dividend per share - most recent fiscal year | — |
| Dividends per share - trailing 12 month | 0.000 |
| EBITD per share - trailing 12 month | 19.591 |
| EPS Basic excluding extraordinary items - most recent fiscal year | 15.460 |
| EPS Basic excluding extraordinary items - trailing 12 month | 17.320 |
| EPS including extraordinary items - most recent fiscal year | 15.460 |
| EPS including extraordinary items - trailing 12 month | 17.320 |
| Free Cash Flow per share - trailing 12 month | 17.423 |
Valuation multiples such as P/E, price to sales, price to book and enterprise value ratios, sourced from Morningstar.
| P/E excluding extraordinary items, most recent fiscal year | 30.85 |
| P/E Normalized, most recent fiscal year | 27.82 |
| Price to sales - most recent fiscal year | 10.78 |
| Price to Tangible Book - most fiscal year | 7.16 |
| Price to Free Cash Flow per Share - most recent fiscal year | 30.40 |
| Price to Cash Flow per share - trailing 12 month | 27.36 |
| Price to Book - most recent fiscal year | 6.63 |
| P/E excluding extraordinary items high, trailing 12 months | 34.07 |
| P/E excluding extraordinary items low, trailing 12 months | 25.18 |
| Net Debt, LFI | -5,874.80 |
| Net Debt, LFY | -4,577.60 |
| Dividend Yield - 5 Year Average | — |
| Dividend Yield - indicated annual dividend divided by closing price | — |
| Current Dividend Yield - Common Stock Primary Issue, LTM | 0.00% |
Cash flow, liquidity and leverage measures, sourced from Morningstar.
| Free Cash Flow - most recent fiscal year | 4,392.90 |
| LT debt/equity - most recent fiscal year | 10.46% |
| Payout ratio - most recent fiscal year | — |
| Total debt/total equity - most recent fiscal year | 10.88% |
| LT debt/equity - most recent quarter | 9.77% |
| Total debt/total equity - most recent quarter | 9.77% |
| Free Cash Flow - trailing 12 month | 4,464.60 |
| Payout ratio - trailing 12 month | — |
Key income statement lines for the most recent fiscal year, in millions, sourced from Morningstar.
| Revenue - most recent fiscal year | 12,001.30 |
| Revenue - trailing 12 month | 12,587.20 |
| EBITD - most recent fiscal year | 4,375.40 |
| EBITD - trailing 12 month | 5,020.20 |
| Earnings before taxes - most recent fiscal year | 4,643.20 |
| Earnings before taxes - trailing 12 month | 5,274.50 |
| Net Income available to common - most recent fiscal year | 3,953.20 |
| Net Income available to common - trailing 12 months | 4,405.20 |
| Earnings before taxes Normalized - most recent fiscal year | 5,710.20 |
| Net Income Available to Common, Normalized - most recent fiscal year | 4,747.00 |
| Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding, TTM | 19.04 |
Profitability margins for the most recent fiscal year, sourced from Morningstar.
| Net Profit Margin % - 1st historical fiscal year | 32.94% |
| Net Profit Margin % - trailing 12 month | 35.00% |
| Operating margin - 1st historical fiscal year | 37.95% |
| Operating margin - trailing 12 month | 37.95% |
| Pretax margin - trailing 12 month | 41.90% |
| Pretax margin - 1st historical fiscal year | 38.69% |
| Operating Margin - 5 year average | 31.68% |
| Pretax Margin - 5 year average | 33.75% |
| Free Operating Cash Flow/Revenue, 5 Year Average | 28.29% |
| Free Operating Cash Flow/Revenue, TTM | 35.47% |
| Net Profit Margin - 5 year average | 26.57% |
Returns on average assets and equity for the fiscal year, the trailing 12 months and as 5 year averages, and net income and revenue per employee in whole currency, sourced from Morningstar.
| Return on average assets - most recent fiscal year | 16.48% |
| Return on average assets - trailing 12 month | 17.15% |
| Return on average equity - most recent fiscal year | 22.97% |
| Return on average equity - trailing 12 month | 23.74% |
| Return on average assets - 5 year average | 14.39% |
| Return on average equity - 5 year average | 19.23% |
| Net Income/employee - most recent fiscal year | 617,687.50 |
| Revenue/employee - most recent fiscal year | 1,875,203.13 |
Growth in revenue, earnings, dividends and book value over recent periods, sourced from Morningstar.
| Revenue growth rate, 5 year | 14.10% |
| EPS growth rate, 5 year | 8.29% |
| Growth rate% - dividend, 3 year | — |
| Revenue/share (5 yr growth) | 14.57% |
| Growth rate% - Revenue, 3 year | 10.35% |
| Growth rate% - EPS, 3 year | 6.12% |
| Book value per share growth rate, 5 year | 17.07% |
| Capital Spending growth rate, 5 year | 10.99% |
| Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR | 6.05% |
Displays analyst’s forecasts for key measures. The estimates can be expanded to see the spread of the calls. Full lines = reported, and dotted lines are forward estimates. Click a measure to add or remove it from the chart, sourced from Morningstar.
Financial forecast (USD, millions except per share)
| Actuals | Estimates | |||||||
| 2025 | 2026 | 2027 | 2028 | 2029 | ||||
| Estimate breakdown | ||||||||
Financial metrics can be plotted on the graph to see trends. Multiple metrics from multiple statements can be plotted against each other, sourced from Morningstar.
Financials (USD, millions)
| Period end: | DEC 21 | DEC 22 | DEC 23 | DEC 24 | DEC 25 |
| Fiscal year: | 2021 | 2022 | 2023 | 2024 | 2025 |
| Period length: | 12 months | 12 months | 12 months | 12 months | 12 months |
Displays all company announcements released by the company to the exchange, sourced from Morningstar.
Announcements
Announcements are available for ASX-listed companies only.
Opinion
No opinions for this company yet.
Action
No actions for this company yet.
Business Summary
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
Relevant suggested news and content from the site
Video
WATCH
Webinar Recording: Are commodities entering a Supercycle?
Recorded Wednesday 24th June @ 12.30pm
Podcast
LISTEN
Thursday 11th September – Dow off -220pts, SPI off -20pts
Daily Podcast Direct from the Desk
Video
WATCH
Buy Hold Sell: The 6 income stocks readers love, plus 2 expert ideas
Recorded 10th June 2026
Podcast
LISTEN
Wednesday 10th September – Dow up +196pts, SPI down -4pts
Daily Podcast Direct from the Desk
